Charles Lu

发表

Human papillomavirus and survival of patients with oropharyngeal cancer.

K. Ang, R. Weber, C. Chung, 2010, The New England journal of medicine.

Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial

A. Garden, M. Chambers, C. Fuller, 2019, Supportive Care in Cancer.

Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis

Robert K. Yu, M. Chambers, Jian Wang, 2017, PloS one.

The Effects of Liver Disease on Surgical Outcomes Following Adult Spinal Deformity Surgery.

Samuel K. Cho, Charles Lu, Samuel J. W. White, 2019, World neurosurgery.

Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial.

B. Yeap, Jack Clark, Charles Lu, 2011, Journal of Clinical Oncology.

Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.

Joe Y. Chang, Xiaodong Zhang, Steven H. Lin, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Aberrant Promoter Methylation Profile and Association with Survival in Patients with Non–Small Cell Lung Cancer

M. Spitz, J. Gu, Xifeng Wu, 2006, Clinical Cancer Research.

Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer.

Joe Y. Chang, P. Thall, D. Gomez, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline.

E. Sturgis, R. Tishler, J. Waldron, 2017, Practical radiation oncology.

Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia.

L. Elting, S. Giordano, R. Gralla, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome.

K. Ang, R. Weber, Q. Zhang, 2010 .

Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer

Michelle D. Williams, W. William, G. Gunn, 2017, Head & neck.

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.

S. Armato, P. Jänne, Helen X. Chen, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians.

Joe Y. Chang, J. Gu, Xifeng Wu, 2014, Cancer research.

Wnt Signaling Pathway Pharmacogenetics in Non-Small Cell Lung Cancer

M. Spitz, Xifeng Wu, Y. Ye, 2014, The Pharmacogenomics Journal.

Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.

Michelle D. Williams, W. William, S. Lai, 2017, Thyroid : official journal of the American Thyroid Association.

Thyroid Gland Malignancies.

Michelle D. Williams, G. Gunn, S. Lai, 2015, Hematology/oncology clinics of North America.

Genetic Variations in the Regulator of G-Protein Signaling Genes Are Associated with Survival in Late-Stage Non-Small Cell Lung Cancer

J. Gu, Xifeng Wu, J. Roth, 2011, PloS one.

Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors

Robert K. Yu, A. Garden, M. Chambers, 2022, Scientific Reports.

Determinants of patient‐reported xerostomia among long‐term oropharyngeal cancer survivors

A. Garden, M. Chambers, S. Shete, 2021, Cancer.

Deficient G2-M and S Checkpoints are Associated with Increased Lung Cancer Risk: A Case-Control Analysis

M. Spitz, Hushan Yang, Xifeng Wu, 2007, Cancer Epidemiology Biomarkers & Prevention.

Value of p 16 INK 4 a and RASSF 1 A Promoter Hypermethylation in Prognosis of Patients with Resectable Non – Small Cell Lung Cancer

Diane D. Liu, W. Hong, J. Lee, 2004 .

A Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Efficacy and Toxicity

R. Weber, T. Pajak, R. Wheeler, 2010 .

lLong-Term Outcomes after Proton Therapy, with Concurrent Chemotherapy, for Stage II-III Inoperable Non-Small Cell Lung Cancer

Joe Y. Chang, Z. Liao, L. Levy, 2016 .

High Mutagen Sensitivity in Peripheral Blood Lymphocytes Predicts Poor Overall and Disease-Specific Survival in Patients with Stage III Non–Small Cell Lung Cancer Treated with Radiotherapy and Chemotherapy

Joe Y. Chang, M. Spitz, Xifeng Wu, 2005, Clinical Cancer Research.

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Edward S. Kim, W. R. Bishop, P. Thall, 2004, Clinical Cancer Research.

ATM sequence variants associate with susceptibility to non‐small cell lung cancer

M. Spitz, Hushan Yang, Xifeng Wu, 2007, International journal of cancer.

Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.

J. Roth, I. Wistuba, J. Lee, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.

J. Heymach, A. Tsao, L. Byers, 2022, Cancer cell.

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

N. Ajami, J. Roth, I. Wistuba, 2021, Nature Medicine.

HighMutagen Sensitivity in Peripheral Blood Lymphocytes Predicts Poor Overall and Disease-Specific Survival in Patients with Stage IIINon^Small Cell Lung Cancer Treatedwith Radiotherapy and Chemotherapy

Joe Y. Chang, M. Spitz, C. Stevens, 2005 .

O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trial

R. Herbst, P. Fidias, J. Heymach, 2005 .

Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial.

E. Bruera, G. Eapen, A. Tsao, 2016, Journal of pain and symptom management.

Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers.

Joe Y. Chang, V Shane Pankratz, Yuanqing Ye, 2013, Cancer research.

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

I. Wistuba, J. Heymach, K. Kelly, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of Telomere-Associated Genes as Prognostic Markers for Overall Survival in Patients with Non–Small Cell Lung Cancer

M. Spitz, J. Gu, Xifeng Wu, 2006, Clinical Cancer Research.

Expressionof Telomere-AssociatedGenes as PrognosticMarkers for Overall Survival in Patients with Non ^ Small Cell Lung Cancer

M. Spitz, J. Gu, Xifeng Wu, 2006 .

Toxicity and Survival after Intensity-Modulated Proton Therapy (IMPT) versus Passive Scattering Proton Therapy (PSPT) for Non-Small Cell Lung Cancer.

Joe Y. Chang, Steven H. Lin, X. Zhu, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Assessing suspected spinal cord

P. Wen, F. Jolesz, F. Drislane, 1999 .

Suspected spinal cord compression in cancer patients: a multidisciplinary risk assessment.

R. Gonzalez, P. Wen, F. Jolesz, 2005, The journal of supportive oncology.

A Phase III Trial to Compare Standard Versus Accelerated Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Compliance and Toxicity

R. Weber, T. Pajak, D. Rosenthal, 2007 .

Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma.

M. Routbort, Li Xu, Wenyi Wang, 2022, JCO precision oncology.

Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.

R. Mohan, M. Martel, P. Balter, 2012, International journal of radiation oncology, biology, physics.

Cohort study of oncologic emergencies in patients with head and neck cancer

M. Chambers, S. Shete, S. Yeung, 2017, Head & neck.

Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer

Diane D. Liu, F. Khuri, W. Hong, 2000 .

Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)

Helen X. Chen, D. Gandara, E. Vokes, 2007 .

Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non–Small Cell Lung Cancer: Final Results of a Phase 2 Study

Joe Y. Chang, R. Mohan, Xiaodong Zhang, 2017, JAMA oncology.

Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial.

Joe Y. Chang, Steven H. Lin, Z. Liao, 2022, Lung cancer.

Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians.

Dong Liang, Jian Gu, Xifeng Wu, 2005, Mutation research.

Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.

R. Herbst, C. Stevens, R. Komaki, 2004, International journal of radiation oncology, biology, physics.

Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.

F. Khuri, A. Gramza, B. Haugen, 2014, Thyroid : official journal of the American Thyroid Association.

Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

Jason M. Johnson, R. Weber, J. Wargo, 2021, Clinical Cancer Research.

Establishing a GMP manufacturing site for nanoparticles

Kai Xu, Lin Ji, Charles Lu, 2007 .

Value of p16INK4a and RASSF1A Promoter Hypermethylation in Prognosis of Patients with Resectable Non–Small Cell Lung Cancer

Diane D. Liu, W. Hong, J. Lee, 2004, Clinical Cancer Research.

Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.

W. Hong, S. Swisher, R. Perez-soler, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.

M. Spitz, J. Gu, Xifeng Wu, 2011, Lung cancer.

Genetic Variants in Cell Cycle Control Pathway Confer Susceptibility to Lung Cancer

M. Spitz, Hushan Yang, Xifeng Wu, 2007, Clinical Cancer Research.

Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians.

M. Spitz, J. Gu, Xifeng Wu, 2006, Carcinogenesis.

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

M. Suarez‐Almazor, H. Tawbi, S. Patel, 2022, Nature Communications.

Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.

Li Mao, B Nebiyou Bekele, Fadlo R Khuri, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer

K. Hess, F. Meric-Bernstam, R. Broaddus, 2018, Oncotarget.

Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.

Radhe Mohan, Stephen M Hahn, John V Heymach, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.

A. Bleyer, H. Choy, J. Lee, 2010, Journal of the National Cancer Institute.

Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy

Joe Y. Chang, M. Spitz, Hushan Yang, 2008, Pharmacogenetics and genomics.

Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.

M. Spitz, S. Lippman, J. Gu, 2011, Carcinogenesis.

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

V. Papadimitrakopoulou, M. Kies, J. Chiao, 2008, Investigational New Drugs.

The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma

Diane D. Liu, F. Khuri, J. Lee, 2002, Cancer.

Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial

J. Lee, F. Meric-Bernstam, D. Kaya, 2021, Advances in Therapy.

277 Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy

J. Roth, S. Swisher, A. Tsao, 2020, Journal for ImmunoTherapy of Cancer.

Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer.

P. Thall, D. Gomez, Steven H. Lin, 2022, Cancer treatment and research communications.

Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors

R. Herbst, M. Truong, F. Fossella, 2004, Cancer Chemotherapy and Pharmacology.

Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma : An ASTRO Evidence Based Clinical Practice Guideline

E. Sturgis, R. Tishler, J. Waldron, 2016 .

Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans

J. Roth, I. Wistuba, J. Lee, 2012, PloS one.

Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk.

M. Spitz, Xifeng Wu, M. Schabath, 2005, American journal of epidemiology.

Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.

Jian Gu, Joe Y. Chang, Yuanqing Ye, 2011, Journal of the National Cancer Institute.

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Kwok-Kin Wong, Zhi Tan, John V. Heymach, 2018, Nature Medicine.

Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019.

E. Sturgis, M. Hofmann, G. Gunn, 2020, JAMA oncology.

Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer.

M. Spitz, S. Lippman, J. Gu, 2011, Carcinogenesis.

Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC

Joe Y. Chang, P. Thall, Steven H. Lin, 2020 .

Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer.

Joe Y. Chang, D. Gomez, R. Komaki, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non–Small Cell Lung Cancer

I. Wistuba, J. Lee, S. Swisher, 2020, Clinical Cancer Research.

A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC

R. Herbst, P. Fidias, D. Prager, 2005 .

Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: A prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory‐Head and Neck Module

Clifton D Fuller, Tito R Mendoza, Charles S Cleeland, 2014, Cancer.

High symptom burden prior to radiation therapy for head and neck cancer: A patient‐reported outcomes study

C. Fuller, C. Cleeland, T. Mendoza, 2012, Head & neck.

Joe Y. Chang, G. Jenkins, R. Weinshilboum, 2014, Clinical pharmacology and therapeutics.

Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study.

A. Garden, C. Fuller, C. Cleeland, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.

R. Komaki, J. Kurie, K. Pisters, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory.

C. Cleeland, T. Mendoza, Z. Liao, 2011, The oncologist.

Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk.

S. Lippman, J. Gu, Xifeng Wu, 2012, Carcinogenesis.

Genetic Variants in Inflammation-Related Genes Are Associated with Radiation-Induced Toxicity Following Treatment for Non-Small Cell Lung Cancer

Joe Y. Chang, M. Spitz, J. Minna, 2010, PloS one.

TGFβ1 Polymorphisms Predict Distant Metastasis–Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy

Q. Wei, R. Komaki, Z. Liao, 2013, PloS one.

Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors.

Aubrey L. White, Jeremy M. Aymard, A. Garden, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck

R. Weber, P. Nagarajan, S. Tam, 2021, Head and Neck.

Levels of symptom burden during chemotherapy for advanced lung cancer: differences between public hospitals and a tertiary cancer center.

C. Cleeland, T. Mendoza, K. Liao, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy and molecularly targeted agents for advanced non-small-cell lung cancer

Charles Lu, 2013 .

Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.

K. Hess, W. William, G. Gunn, 2017, Thyroid : official journal of the American Thyroid Association.

Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer

Joe Y. Chang, R. Komaki, Z. Liao, 2011, Cancer.

Phase 2 study of high‐dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer

Joe Y. Chang, R. Mohan, R. Komaki, 2011, Cancer.

Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base

A. Garden, C. Fuller, D. Rosenthal, 2017, Cancer.

Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study

M. Hofmann, M. Spiotto, G. Gunn, 2023, Thyroid : official journal of the American Thyroid Association.

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma

C. Fuller, E. Sturgis, D. Rosenthal, 2019, Thyroid : official journal of the American Thyroid Association.

Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer

Bradley J. Barney, V. Johnson, C. Cleeland, 2013, Quality of Life Research.

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status Do Not Make a Difference

C. Cleeland, C. Fagundes, Charles Lu, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Initial Medical Attention on Patients with Early-Stage Non-Small Cell Lung Cancer

I. Gorlov, M. Kimmel, O. Gorlova, 2012, PloS one.

OA 12.01 The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC

K. Politi, R. Doebele, A. Tsao, 2017 .

Association between glutathione S‐transferase π polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma

Joe Y. Chang, M. Spitz, W. Hong, 2006, Cancer.

A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries.

Maureen B. Fagan, Michael E. Miller, Erich J. Greene, 2020, The New England journal of medicine.

Nomogram for Predicting Symptom Severity during Radiation Therapy for Head and Neck Cancer

A. Garden, C. Fuller, C. Cleeland, 2014, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Suspected spinal cord compression in breast cancer patients: A multidisciplinary risk assessment

P. Wen, F. Jolesz, F. Drislane, 1998, Breast Cancer Research and Treatment.

Pharmacogenetics in esophageal cancer.

J. Ajani, Xifeng Wu, Charles Lu, 2005, Seminars in oncology.

Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer

Qiuling Shi, Tito R Mendoza, Charles S Cleeland, 2009, Cancer.

Systemic therapy with tumor suppressor FUS1-nanoparticles for stage IV lung cancer

J. Roth, R. Ramesh, M. Hicks, 2007 .

Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non–Small Cell Lung Cancer

D. Gomez, R. Komaki, Z. Liao, 2017, American journal of clinical oncology.

OA13.06 Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer - NEOSTAR Study

J. Roth, S. Swisher, A. Tsao, 2019, Journal of Thoracic Oncology.